BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36748186)

  • 1. Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta-analysis.
    Joshi SR; Singh G; Marwah A; Mittra S; Suvarna VR; Athalye SN
    Diabetes Obes Metab; 2023 Jun; 25(6):1589-1606. PubMed ID: 36748186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
    Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
    Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, efficacy, and cost-effectiveness of insulin degludec U100 versus insulin glargine U300 in adults with type 1 diabetes: a systematic review and indirect treatment comparison.
    Martin ; Zhou Y; Takagi T; Tian YS
    Int J Clin Pharm; 2022 Jun; 44(3):587-598. PubMed ID: 35476308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
    Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
    Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).
    Matsuhisa M; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T;
    Diabetes Obes Metab; 2016 Apr; 18(4):375-83. PubMed ID: 26662964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).
    Bolli GB; Riddle MC; Bergenstal RM; Ziemen M; Sestakauskas K; Goyeau H; Home PD;
    Diabetes Obes Metab; 2015 Apr; 17(4):386-94. PubMed ID: 25641260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013498. PubMed ID: 33662147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.
    Yale JF; Aroda VR; Charbonnel B; Sinclair AJ; Trescoli C; Cahn A; Bigot G; Merino-Trigo A; Brulle-Wohlhueter C; Bolli GB; Ritzel R
    Diabetes Metab; 2020 Apr; 46(2):110-118. PubMed ID: 30366067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials.
    Rosenstock J; Marre M; Qu Y; Zhang S; Bastyr EJ; Prince MJ; Chang AM
    Diabetes Obes Metab; 2016 Nov; 18(11):1093-1097. PubMed ID: 27484021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
    Pettus J; Gill J; Paranjape S; Stewart J; Malla S; Edelman S; Bergenstal RM; Bode B
    Diabetes Obes Metab; 2019 Aug; 21(8):1906-1913. PubMed ID: 30993855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
    Goldman J; White JR
    Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.
    Lingvay I; Chao J; Dalal MR; Meneghini LF
    Diabetes Technol Ther; 2017 May; 19(5):315-322. PubMed ID: 28467113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
    Al Malki F; El Damanhoury B; Othman A; Alghamdi Z; AlQahtani M; Madgy A; Chouikrat Z
    Diabetes Obes Metab; 2023 Oct; 25(10):2869-2877. PubMed ID: 37485767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.
    Freemantle N; Chou E; Frois C; Zhuo D; Lehmacher W; Vlajnic A; Wang H; Chung HW; Zhang Q; Wu E; Gerrits C
    BMJ Open; 2016 Feb; 6(2):e009421. PubMed ID: 26880669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
    Ritzel R; Ghosh S; Emral R; Malek R; Zeng L; Mabunay MA; Landgraf W; Guyot P; Serafini P; Pushkarna D; Malik RA
    Diabetes Obes Metab; 2023 Sep; 25(9):2495-2504. PubMed ID: 37312665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
    Battelino T; Danne T; Edelman SV; Choudhary P; Renard E; Westerbacka J; Mukherjee B; Pilorget V; Coudert M; Bergenstal RM
    Diabetes Obes Metab; 2023 Feb; 25(2):545-555. PubMed ID: 36263928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus insulin glargine 100 U/ml in people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: the EDITION 2 randomized 12-month trial including 6-month extension.
    Yki-Järvinen H; Bergenstal RM; Bolli GB; Ziemen M; Wardecki M; Muehlen-Bartmer I; Maroccia M; Riddle MC
    Diabetes Obes Metab; 2015 Dec; 17(12):1142-9. PubMed ID: 26172084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
    Zhang XW; Zhang XL; Xu B; Kang LN
    Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
    Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
    Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.